ALAMO, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) — Synergys Biotherapeutics, a preclinical stage biotherapeutics firm growing Vasculogenic Mimicry (VM)-blocking antibody fusion medicine, introduced at present that it has been awarded a Phase I/Phase II Fast-Track grant from the National Cancer Institute below the auspices of the Small Business Innovation Research (SBIR) program of the National Institutes of Health. The grant will help ongoing preclinical growth of the Company’s lead organic drug candidate, SYN-001, as a therapy for Triple Negative Breast Cancer (TNBC). SYN-001 is a novel antibody fusion therapeutic that hyperlinks an anti-EGFR antibody to a extremely anti-angiogenic dimeric mutant endostatin as its fusion associate.
The Fast-Track grant features a 1-year Phase l funding for efficacy research of SYN-001 in TNBC patient-derived xenograft (PDX) fashions which is able to complement efficacy outcomes already obtained from TNBC cell line primarily based xenografts that had been lately printed within the journal CELLS (Cells 2021,10,2904. https://doi.org/10.3390/cells10112904). Contingent on Phase I success, Phase II funds for two years will likely be allowed to hold out additional research important for submitting an IND.
SYN-001 is an thrilling new and modern focused “immuno-anti-vasculogenesis” therapeutic for prevention of TNBC progress and metastases. In addition to anti-angiogenic exercise directed at endothelial cells, SYN-001 is uniquely able to inhibiting vasculogenic mimicry, i.e. the direct formation of vascular channels by TNBC cells. SYN-001 additionally inhibits TNBC tumor cell motility, migration and metastasis, and retains ADCC exercise. Unlike SYN-001, most currently-marketed anti-angiogenic medicine lack vital VM-inhibitory exercise.
Synergys will develop SYN-001 in collaboration with Joseph Rosenblatt, M.D., Professor of Medicine, Microbiology and Immunology, and Sundaram Ramakrishnan, Ph.D., Professor of Surgery, each from the University of Miami/Sylvester Comprehensive Cancer Center, Miami, FL. The laboratory of Dr. Rosenblatt, the tutorial co-PI of the undertaking, initially designed the SYN-001 fusion protein and demonstrated the flexibility of SYN-001 to dam VM and metastases by TNBC cells.
Regarding the award, Dr. Rosenblatt notes, “We are delighted that NCI has continued its recognition of our collaborative research with Synergys on inhibition of Vasculogenic Mimicry in TNBC by SYN-001. The current Fast-Track award has followed on the heels of two recently completed Phase I SBIR grant, one of which involved the development of SYN-001 for TNBC. We look forward to expanding our highly productive collaboration with Synergys for the preclinical development of SYN-001.”
“We are extremely grateful to the NCI grant overview committee for recognizing Synergys’ vastly impactful analysis in the direction of offering a brand new therapeutic therapy for TNBC,” said Rathin Das, Ph.D, Founder and Chief Executive Officer of Synergys. “The planned studies for which NCI has awarded us the Fast Track grant will facilitate progress in preclinical development of SYN-001 for submission of an IND as a first-in-class biotherapeutic for human testing involving TNBC patients.”
Dr. Das additional mentioned, “We will continue to aggressively pursue securing government grants as non-dilutive funding in addition to external investment and partnerships for developing our pipeline candidates”.
About Synergys Biotherapeutics
Synergys is a preclinical stage biotherapeutics company developing Vasculogenic Mimicry-blocking Antibody Fusion products for treatment of various cancers. The Company’s most advanced product candidate, Anti-EGFR-TAP (SYN-001) is currently in preclinical development for Triple Negative Breast Cancer. Additionally, a second candidate, Anti-HER2-TAP (SYN-002) is being developed for ovarian cancer. Both candidates were derived from the technology termed A-TAP (Antibody-Targeted Anti-vascularization Payload). Synergys utilizes a virtual business model and works with its academic partners and various CROs for the development of its therapeutic candidates.
Contacts
Dr. Rathin C. Das
Chief Executive Officer
Synergys Biotherapeutics, Inc.
Ph: 925-575-0181
email: [email protected]
https://www.Synergysbio.com
